CD44 and neoplasm: However, no difference was observed in recurred tumors between DTX and DTX + mAb17 groups in the expression levels of PLXNB2 and CSC markers including ITGA6 (CD49f), PROM1 (CD133), CD24, and CD44 (Fig. 6c), suggesting that delayed tumor recurrence in the combinatorial treatment group was not due to changes of clonal composition induced by PLXNB2 inhibition.